Benchmarking total hip replacement constructs using noninferiority analysis: the New Zealand joint registry study.


Journal

BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565

Informations de publication

Date de publication:
21 Aug 2021
Historique:
received: 21 10 2020
accepted: 03 08 2021
entrez: 22 8 2021
pubmed: 23 8 2021
medline: 25 8 2021
Statut: epublish

Résumé

The aim of this study was to compare the relative performance of total hip replacement constructs and discern if there is substantial variability in performance in currently commonly used prostheses in the New Zealand Joint Registry (NZJR) using a noninferiority analysis. All patients who underwent a primary total hip replacement (THR) registered in the NZJR between 1st January 1999 to June 2020 were identified. Using a noninferiority analysis, the performance of hip prostheses were compared with the best performing contemporary construct. Construct failure was estimated using the 1-Kaplan Meier survival function method to estimate net failure. The difference in failure between the contemporary benchmark and other constructs was examined. In total 135,432 THR were recorded comprising 1035 different THR constructs. Notably 328 constructs were used just once. Forty-eight constructs (62,251 THR) had > 500 procedures at risk at 3 years post-primary of which 28 were inferior by at least 20% relative risk of which, 10 were inferior by at least 100% relative risk. Sixteen constructs were identified with > 500 procedures at risk at 10 years with 9 inferior by at least 20%, of which one was inferior by > 100% relative risk. There were fewer constructs noninferior to the best practice benchmark when we performed analysis by gender. In females at 10 years, from 5 constructs with > 500 constructs at risk, 2 were inferior at the 20% margin. In males at 10 years, there were only 2 eligible constructs of which one was inferior at the 20% margin. We discerned that there is substantial variability in construct performance and at most time points, just over half of constructs are inferior to the best performing construct by at least 20%. These results can facilitate informed decision-making when considering THR surgery.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to compare the relative performance of total hip replacement constructs and discern if there is substantial variability in performance in currently commonly used prostheses in the New Zealand Joint Registry (NZJR) using a noninferiority analysis.
METHODS METHODS
All patients who underwent a primary total hip replacement (THR) registered in the NZJR between 1st January 1999 to June 2020 were identified. Using a noninferiority analysis, the performance of hip prostheses were compared with the best performing contemporary construct. Construct failure was estimated using the 1-Kaplan Meier survival function method to estimate net failure. The difference in failure between the contemporary benchmark and other constructs was examined.
RESULTS RESULTS
In total 135,432 THR were recorded comprising 1035 different THR constructs. Notably 328 constructs were used just once. Forty-eight constructs (62,251 THR) had > 500 procedures at risk at 3 years post-primary of which 28 were inferior by at least 20% relative risk of which, 10 were inferior by at least 100% relative risk. Sixteen constructs were identified with > 500 procedures at risk at 10 years with 9 inferior by at least 20%, of which one was inferior by > 100% relative risk. There were fewer constructs noninferior to the best practice benchmark when we performed analysis by gender. In females at 10 years, from 5 constructs with > 500 constructs at risk, 2 were inferior at the 20% margin. In males at 10 years, there were only 2 eligible constructs of which one was inferior at the 20% margin.
CONCLUSIONS CONCLUSIONS
We discerned that there is substantial variability in construct performance and at most time points, just over half of constructs are inferior to the best performing construct by at least 20%. These results can facilitate informed decision-making when considering THR surgery.

Identifiants

pubmed: 34419036
doi: 10.1186/s12891-021-04602-0
pii: 10.1186/s12891-021-04602-0
pmc: PMC8380353
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

719

Informations de copyright

© 2021. The Author(s).

Références

BMJ Open. 2017 Aug 28;7(8):e015397
pubmed: 28851772
Lancet. 2017 Apr 8;389(10077):1424-1430
pubmed: 28209371
BMJ Open. 2019 Apr 29;9(4):e026685
pubmed: 31036708
Acta Orthop Scand. 2002 Aug;73(4):400-2
pubmed: 12358111
Bone Joint J. 2020 Apr;102-B(4):414-422
pubmed: 32228075
PLoS Med. 2020 Aug 31;17(8):e1003291
pubmed: 32866147
Acta Orthop. 2018 Jun;89(3):256-258
pubmed: 29521152
Hip Int. 2018 Jul;28(4):352-362
pubmed: 29192727
Trials. 2011 May 03;12:106
pubmed: 21539749
BMJ. 1998 Feb 28;316(7132):650
pubmed: 9522782
Lancet. 2012 Nov 17;380(9855):1759-66
pubmed: 23036895
N Z Med J. 2013 Jun 28;126(1377):5-6
pubmed: 23831871

Auteurs

Michael Wyatt (M)

Massey University, Manawatu Campus, Palmerston North, New Zealand. michaelcharleswyatt@icloud.com.

Chris Frampton (C)

Massey University, Manawatu Campus, Palmerston North, New Zealand.

Michael Whitehouse (M)

Massey University, Manawatu Campus, Palmerston North, New Zealand.

Kevin Deere (K)

Massey University, Manawatu Campus, Palmerston North, New Zealand.

Adrian Sayers (A)

Massey University, Manawatu Campus, Palmerston North, New Zealand.

David Kieser (D)

Massey University, Manawatu Campus, Palmerston North, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH